Giorgio Cruccu


Affiliation: University of Rome La Sapienza
Country: Italy


  1. Di Stefano G, Truini A, Cruccu G. Current and Innovative Pharmacological Options to Treat Typical and Atypical Trigeminal Neuralgia. Drugs. 2018;78:1433-1442 pubmed publisher
    ..Future trials testing the effect of combination therapy in patients with TN are needed, especially in patients with concomitant continuous pain and in TN secondary to multiple sclerosis. ..
  2. Cruccu G, Pennisi E, Antonini G, Biasiotta A, Di Stefano G, La Cesa S, et al. Trigeminal isolated sensory neuropathy (TISN) and FOSMN syndrome: despite a dissimilar disease course do they share common pathophysiological mechanisms?. BMC Neurol. 2014;14:248 pubmed publisher
  3. Truini A, Piroso S, Pasquale E, Notartomaso S, Di Stefano G, Lattanzi R, et al. N-acetyl-cysteine, a drug that enhances the endogenous activation of group-II metabotropic glutamate receptors, inhibits nociceptive transmission in humans. Mol Pain. 2015;11:14 pubmed publisher
    ..These data lay the groundwork for investigating the therapeutic potential of NAC in patients with chronic pain. ..
  4. Cruccu G, Truini A. A review of Neuropathic Pain: From Guidelines to Clinical Practice. Pain Ther. 2017;6:35-42 pubmed publisher
    ..This chapter discusses clinical practice guidelines for neuropathic pain and their usefulness in clinical practice. Pfizer, Italy. ..
  5. Cruccu G, Di Stefano G, Fattapposta F, Jann S, Padua L, Schenone A, et al. L-Acetyl-carnitine in Patients with Carpal Tunnel Syndrome: Effects on Nerve Protection, Hand Function and Pain. CNS Drugs. 2017;31:1103-1111 pubmed publisher
    ..LAC reduced pain in patients with mild and moderate CTS, a result that is possibly due to both its neuroprotective action and its central anti-nociceptive properties. Clinical Trials Registration code: EudraCT 2014-002289-62. ..